Global Artificial Blood

Artificial Blood Comprehensive Study by Type (Human Blood, Synthetic Blood, Animal Blood), Application (Cardiovascular diseases, Anemia, Organ transplant, Trauma, Others), End-use (Hospitals, Clinics, Blood banks, Others) Players and Region - Global Market Outlook to 2028

Artificial Blood Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Artificial blood is sometimes known as a blood substitute or a blood surrogate. Artificial blood is a novel idea in transfusion medicine in which specially made compounds replace the role of allogenic human blood transfusion by transporting and delivering oxygen in the body. These dark crimson or burgundy blood replacements are frequently derived from RBCs of expired human blood, cow blood, hemoglobin-producing genetically engineered microorganisms, or human placentas. The synthetic haemoglobin molecules have been tweaked to form a strong structure and to function without the protective cover of RBCS.This growth is primarily driven by Rising demand for blood transfusion .

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Volume UnitK Units
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Health Care Facilities sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Dextro-Sang Corporation (United States), BioPure Corporation (United States), Sangart (United States), Northfield Laboratories (United States), Baxter International (United States), FluorO2 Therapeutics (United States), Nuvox Pharma (United States), Alpha Therapeutic Corporation (United States), HemoBioTech (United States) and Hemarina (France), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In March 2021, Hemarina demonstrated the anti-inflammatory and antibacterial properties of M101 for the treatment of periodontitis. This study validated the qualities of Hemarina’s technological platform, based on the M101 molecule, an “oxygen carrier” derived from the haemoglobin of the marine worm.
In 2020, NuvOx Pharma Announces Appointment of Jon S. Saxe to Its Board of Directors. Saxe brings to NuvOx many years of experience from the biotechnology, pharmaceutical and venture capital industries. He has served as a director of more than 25 companies and currently is a director of several publicly traded biotechnology companies including Vistagen Therapeutics and DURECT Corporation as well as a number of private companies. He was president of PDL BioPharma Protein and also was president and CEO of Synergen, a biotechnology company purchased by Amgen. Prior to his work at biotech companies Saxe was vice president of licensing and corporate development and head of patent law for Hoffmann-LaRoche Inc., where he worked for 29 years.The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth.

Influencing Trend:
Introduction to new blood technology

Market Growth Drivers:
Rising demand for blood transfusion and Increasing prevalence diseases

Challenges:
Shortage of availability of blood

Restraints:
High cost associated with bloods

Opportunities:
Growing awareness of blood donation

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Artificial Blood Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Artificial Blood Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Artificial Blood players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Artificial Blood Study Sheds Light on
— The Artificial Blood Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Artificial Blood industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Artificial Blood industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Human Blood
  • Synthetic Blood
  • Animal Blood
By Application
  • Cardiovascular diseases
  • Anemia
  • Organ transplant
  • Trauma
  • Others
By End-use
  • Hospitals
  • Clinics
  • Blood banks
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising demand for blood transfusion
      • 3.2.2. Increasing prevalence diseases
    • 3.3. Market Challenges
      • 3.3.1. Shortage of availability of blood
    • 3.4. Market Trends
      • 3.4.1. Introduction to new blood technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Artificial Blood, by Type, Application, End-use and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Artificial Blood (Value)
      • 5.2.1. Global Artificial Blood by: Type (Value)
        • 5.2.1.1. Human Blood
        • 5.2.1.2. Synthetic Blood
        • 5.2.1.3. Animal Blood
      • 5.2.2. Global Artificial Blood by: Application (Value)
        • 5.2.2.1. Cardiovascular diseases
        • 5.2.2.2. Anemia
        • 5.2.2.3. Organ transplant
        • 5.2.2.4. Trauma
        • 5.2.2.5. Others
      • 5.2.3. Global Artificial Blood by: End-use (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Blood banks
        • 5.2.3.4. Others
      • 5.2.4. Global Artificial Blood Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Artificial Blood (Volume)
      • 5.3.1. Global Artificial Blood by: Type (Volume)
        • 5.3.1.1. Human Blood
        • 5.3.1.2. Synthetic Blood
        • 5.3.1.3. Animal Blood
      • 5.3.2. Global Artificial Blood by: Application (Volume)
        • 5.3.2.1. Cardiovascular diseases
        • 5.3.2.2. Anemia
        • 5.3.2.3. Organ transplant
        • 5.3.2.4. Trauma
        • 5.3.2.5. Others
      • 5.3.3. Global Artificial Blood by: End-use (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
        • 5.3.3.3. Blood banks
        • 5.3.3.4. Others
      • 5.3.4. Global Artificial Blood Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Artificial Blood (Price)
      • 5.4.1. Global Artificial Blood by: Type (Price)
  • 6. Artificial Blood: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Dextro-Sang Corporation (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. BioPure Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sangart (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Northfield Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Baxter International (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. FluorO2 Therapeutics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Nuvox Pharma (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Alpha Therapeutic Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. HemoBioTech (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Hemarina (France)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Artificial Blood Sale, by Type, Application, End-use and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Artificial Blood (Value)
      • 7.2.1. Global Artificial Blood by: Type (Value)
        • 7.2.1.1. Human Blood
        • 7.2.1.2. Synthetic Blood
        • 7.2.1.3. Animal Blood
      • 7.2.2. Global Artificial Blood by: Application (Value)
        • 7.2.2.1. Cardiovascular diseases
        • 7.2.2.2. Anemia
        • 7.2.2.3. Organ transplant
        • 7.2.2.4. Trauma
        • 7.2.2.5. Others
      • 7.2.3. Global Artificial Blood by: End-use (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Blood banks
        • 7.2.3.4. Others
      • 7.2.4. Global Artificial Blood Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Artificial Blood (Volume)
      • 7.3.1. Global Artificial Blood by: Type (Volume)
        • 7.3.1.1. Human Blood
        • 7.3.1.2. Synthetic Blood
        • 7.3.1.3. Animal Blood
      • 7.3.2. Global Artificial Blood by: Application (Volume)
        • 7.3.2.1. Cardiovascular diseases
        • 7.3.2.2. Anemia
        • 7.3.2.3. Organ transplant
        • 7.3.2.4. Trauma
        • 7.3.2.5. Others
      • 7.3.3. Global Artificial Blood by: End-use (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
        • 7.3.3.3. Blood banks
        • 7.3.3.4. Others
      • 7.3.4. Global Artificial Blood Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Artificial Blood (Price)
      • 7.4.1. Global Artificial Blood by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Artificial Blood: by Type(USD Million)
  • Table 2. Artificial Blood Human Blood , by Region USD Million (2017-2022)
  • Table 3. Artificial Blood Synthetic Blood , by Region USD Million (2017-2022)
  • Table 4. Artificial Blood Animal Blood , by Region USD Million (2017-2022)
  • Table 5. Artificial Blood: by Application(USD Million)
  • Table 6. Artificial Blood Cardiovascular diseases , by Region USD Million (2017-2022)
  • Table 7. Artificial Blood Anemia , by Region USD Million (2017-2022)
  • Table 8. Artificial Blood Organ transplant , by Region USD Million (2017-2022)
  • Table 9. Artificial Blood Trauma , by Region USD Million (2017-2022)
  • Table 10. Artificial Blood Others , by Region USD Million (2017-2022)
  • Table 11. Artificial Blood: by End-use(USD Million)
  • Table 12. Artificial Blood Hospitals , by Region USD Million (2017-2022)
  • Table 13. Artificial Blood Clinics , by Region USD Million (2017-2022)
  • Table 14. Artificial Blood Blood banks , by Region USD Million (2017-2022)
  • Table 15. Artificial Blood Others , by Region USD Million (2017-2022)
  • Table 16. South America Artificial Blood, by Country USD Million (2017-2022)
  • Table 17. South America Artificial Blood, by Type USD Million (2017-2022)
  • Table 18. South America Artificial Blood, by Application USD Million (2017-2022)
  • Table 19. South America Artificial Blood, by End-use USD Million (2017-2022)
  • Table 20. Brazil Artificial Blood, by Type USD Million (2017-2022)
  • Table 21. Brazil Artificial Blood, by Application USD Million (2017-2022)
  • Table 22. Brazil Artificial Blood, by End-use USD Million (2017-2022)
  • Table 23. Argentina Artificial Blood, by Type USD Million (2017-2022)
  • Table 24. Argentina Artificial Blood, by Application USD Million (2017-2022)
  • Table 25. Argentina Artificial Blood, by End-use USD Million (2017-2022)
  • Table 26. Rest of South America Artificial Blood, by Type USD Million (2017-2022)
  • Table 27. Rest of South America Artificial Blood, by Application USD Million (2017-2022)
  • Table 28. Rest of South America Artificial Blood, by End-use USD Million (2017-2022)
  • Table 29. Asia Pacific Artificial Blood, by Country USD Million (2017-2022)
  • Table 30. Asia Pacific Artificial Blood, by Type USD Million (2017-2022)
  • Table 31. Asia Pacific Artificial Blood, by Application USD Million (2017-2022)
  • Table 32. Asia Pacific Artificial Blood, by End-use USD Million (2017-2022)
  • Table 33. China Artificial Blood, by Type USD Million (2017-2022)
  • Table 34. China Artificial Blood, by Application USD Million (2017-2022)
  • Table 35. China Artificial Blood, by End-use USD Million (2017-2022)
  • Table 36. Japan Artificial Blood, by Type USD Million (2017-2022)
  • Table 37. Japan Artificial Blood, by Application USD Million (2017-2022)
  • Table 38. Japan Artificial Blood, by End-use USD Million (2017-2022)
  • Table 39. India Artificial Blood, by Type USD Million (2017-2022)
  • Table 40. India Artificial Blood, by Application USD Million (2017-2022)
  • Table 41. India Artificial Blood, by End-use USD Million (2017-2022)
  • Table 42. South Korea Artificial Blood, by Type USD Million (2017-2022)
  • Table 43. South Korea Artificial Blood, by Application USD Million (2017-2022)
  • Table 44. South Korea Artificial Blood, by End-use USD Million (2017-2022)
  • Table 45. Taiwan Artificial Blood, by Type USD Million (2017-2022)
  • Table 46. Taiwan Artificial Blood, by Application USD Million (2017-2022)
  • Table 47. Taiwan Artificial Blood, by End-use USD Million (2017-2022)
  • Table 48. Australia Artificial Blood, by Type USD Million (2017-2022)
  • Table 49. Australia Artificial Blood, by Application USD Million (2017-2022)
  • Table 50. Australia Artificial Blood, by End-use USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Artificial Blood, by Type USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Artificial Blood, by Application USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Artificial Blood, by End-use USD Million (2017-2022)
  • Table 54. Europe Artificial Blood, by Country USD Million (2017-2022)
  • Table 55. Europe Artificial Blood, by Type USD Million (2017-2022)
  • Table 56. Europe Artificial Blood, by Application USD Million (2017-2022)
  • Table 57. Europe Artificial Blood, by End-use USD Million (2017-2022)
  • Table 58. Germany Artificial Blood, by Type USD Million (2017-2022)
  • Table 59. Germany Artificial Blood, by Application USD Million (2017-2022)
  • Table 60. Germany Artificial Blood, by End-use USD Million (2017-2022)
  • Table 61. France Artificial Blood, by Type USD Million (2017-2022)
  • Table 62. France Artificial Blood, by Application USD Million (2017-2022)
  • Table 63. France Artificial Blood, by End-use USD Million (2017-2022)
  • Table 64. Italy Artificial Blood, by Type USD Million (2017-2022)
  • Table 65. Italy Artificial Blood, by Application USD Million (2017-2022)
  • Table 66. Italy Artificial Blood, by End-use USD Million (2017-2022)
  • Table 67. United Kingdom Artificial Blood, by Type USD Million (2017-2022)
  • Table 68. United Kingdom Artificial Blood, by Application USD Million (2017-2022)
  • Table 69. United Kingdom Artificial Blood, by End-use USD Million (2017-2022)
  • Table 70. Netherlands Artificial Blood, by Type USD Million (2017-2022)
  • Table 71. Netherlands Artificial Blood, by Application USD Million (2017-2022)
  • Table 72. Netherlands Artificial Blood, by End-use USD Million (2017-2022)
  • Table 73. Rest of Europe Artificial Blood, by Type USD Million (2017-2022)
  • Table 74. Rest of Europe Artificial Blood, by Application USD Million (2017-2022)
  • Table 75. Rest of Europe Artificial Blood, by End-use USD Million (2017-2022)
  • Table 76. MEA Artificial Blood, by Country USD Million (2017-2022)
  • Table 77. MEA Artificial Blood, by Type USD Million (2017-2022)
  • Table 78. MEA Artificial Blood, by Application USD Million (2017-2022)
  • Table 79. MEA Artificial Blood, by End-use USD Million (2017-2022)
  • Table 80. Middle East Artificial Blood, by Type USD Million (2017-2022)
  • Table 81. Middle East Artificial Blood, by Application USD Million (2017-2022)
  • Table 82. Middle East Artificial Blood, by End-use USD Million (2017-2022)
  • Table 83. Africa Artificial Blood, by Type USD Million (2017-2022)
  • Table 84. Africa Artificial Blood, by Application USD Million (2017-2022)
  • Table 85. Africa Artificial Blood, by End-use USD Million (2017-2022)
  • Table 86. North America Artificial Blood, by Country USD Million (2017-2022)
  • Table 87. North America Artificial Blood, by Type USD Million (2017-2022)
  • Table 88. North America Artificial Blood, by Application USD Million (2017-2022)
  • Table 89. North America Artificial Blood, by End-use USD Million (2017-2022)
  • Table 90. United States Artificial Blood, by Type USD Million (2017-2022)
  • Table 91. United States Artificial Blood, by Application USD Million (2017-2022)
  • Table 92. United States Artificial Blood, by End-use USD Million (2017-2022)
  • Table 93. Canada Artificial Blood, by Type USD Million (2017-2022)
  • Table 94. Canada Artificial Blood, by Application USD Million (2017-2022)
  • Table 95. Canada Artificial Blood, by End-use USD Million (2017-2022)
  • Table 96. Mexico Artificial Blood, by Type USD Million (2017-2022)
  • Table 97. Mexico Artificial Blood, by Application USD Million (2017-2022)
  • Table 98. Mexico Artificial Blood, by End-use USD Million (2017-2022)
  • Table 99. Artificial Blood Sales: by Type(K Units)
  • Table 100. Artificial Blood Sales Human Blood , by Region K Units (2017-2022)
  • Table 101. Artificial Blood Sales Synthetic Blood , by Region K Units (2017-2022)
  • Table 102. Artificial Blood Sales Animal Blood , by Region K Units (2017-2022)
  • Table 103. Artificial Blood Sales: by Application(K Units)
  • Table 104. Artificial Blood Sales Cardiovascular diseases , by Region K Units (2017-2022)
  • Table 105. Artificial Blood Sales Anemia , by Region K Units (2017-2022)
  • Table 106. Artificial Blood Sales Organ transplant , by Region K Units (2017-2022)
  • Table 107. Artificial Blood Sales Trauma , by Region K Units (2017-2022)
  • Table 108. Artificial Blood Sales Others , by Region K Units (2017-2022)
  • Table 109. Artificial Blood Sales: by End-use(K Units)
  • Table 110. Artificial Blood Sales Hospitals , by Region K Units (2017-2022)
  • Table 111. Artificial Blood Sales Clinics , by Region K Units (2017-2022)
  • Table 112. Artificial Blood Sales Blood banks , by Region K Units (2017-2022)
  • Table 113. Artificial Blood Sales Others , by Region K Units (2017-2022)
  • Table 114. South America Artificial Blood Sales, by Country K Units (2017-2022)
  • Table 115. South America Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 116. South America Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 117. South America Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 118. Brazil Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 119. Brazil Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 120. Brazil Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 121. Argentina Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 122. Argentina Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 123. Argentina Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 124. Rest of South America Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 125. Rest of South America Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 126. Rest of South America Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 127. Asia Pacific Artificial Blood Sales, by Country K Units (2017-2022)
  • Table 128. Asia Pacific Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 129. Asia Pacific Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 130. Asia Pacific Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 131. China Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 132. China Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 133. China Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 134. Japan Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 135. Japan Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 136. Japan Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 137. India Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 138. India Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 139. India Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 140. South Korea Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 141. South Korea Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 142. South Korea Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 143. Taiwan Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 144. Taiwan Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 145. Taiwan Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 146. Australia Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 147. Australia Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 148. Australia Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 149. Rest of Asia-Pacific Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 150. Rest of Asia-Pacific Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 151. Rest of Asia-Pacific Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 152. Europe Artificial Blood Sales, by Country K Units (2017-2022)
  • Table 153. Europe Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 154. Europe Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 155. Europe Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 156. Germany Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 157. Germany Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 158. Germany Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 159. France Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 160. France Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 161. France Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 162. Italy Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 163. Italy Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 164. Italy Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 165. United Kingdom Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 166. United Kingdom Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 167. United Kingdom Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 168. Netherlands Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 169. Netherlands Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 170. Netherlands Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 171. Rest of Europe Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 172. Rest of Europe Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 173. Rest of Europe Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 174. MEA Artificial Blood Sales, by Country K Units (2017-2022)
  • Table 175. MEA Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 176. MEA Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 177. MEA Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 178. Middle East Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 179. Middle East Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 180. Middle East Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 181. Africa Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 182. Africa Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 183. Africa Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 184. North America Artificial Blood Sales, by Country K Units (2017-2022)
  • Table 185. North America Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 186. North America Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 187. North America Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 188. United States Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 189. United States Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 190. United States Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 191. Canada Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 192. Canada Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 193. Canada Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 194. Mexico Artificial Blood Sales, by Type K Units (2017-2022)
  • Table 195. Mexico Artificial Blood Sales, by Application K Units (2017-2022)
  • Table 196. Mexico Artificial Blood Sales, by End-use K Units (2017-2022)
  • Table 197. Artificial Blood: by Type(USD/Units)
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Artificial Blood: by Type(USD Million)
  • Table 209. Artificial Blood Human Blood , by Region USD Million (2023-2028)
  • Table 210. Artificial Blood Synthetic Blood , by Region USD Million (2023-2028)
  • Table 211. Artificial Blood Animal Blood , by Region USD Million (2023-2028)
  • Table 212. Artificial Blood: by Application(USD Million)
  • Table 213. Artificial Blood Cardiovascular diseases , by Region USD Million (2023-2028)
  • Table 214. Artificial Blood Anemia , by Region USD Million (2023-2028)
  • Table 215. Artificial Blood Organ transplant , by Region USD Million (2023-2028)
  • Table 216. Artificial Blood Trauma , by Region USD Million (2023-2028)
  • Table 217. Artificial Blood Others , by Region USD Million (2023-2028)
  • Table 218. Artificial Blood: by End-use(USD Million)
  • Table 219. Artificial Blood Hospitals , by Region USD Million (2023-2028)
  • Table 220. Artificial Blood Clinics , by Region USD Million (2023-2028)
  • Table 221. Artificial Blood Blood banks , by Region USD Million (2023-2028)
  • Table 222. Artificial Blood Others , by Region USD Million (2023-2028)
  • Table 223. South America Artificial Blood, by Country USD Million (2023-2028)
  • Table 224. South America Artificial Blood, by Type USD Million (2023-2028)
  • Table 225. South America Artificial Blood, by Application USD Million (2023-2028)
  • Table 226. South America Artificial Blood, by End-use USD Million (2023-2028)
  • Table 227. Brazil Artificial Blood, by Type USD Million (2023-2028)
  • Table 228. Brazil Artificial Blood, by Application USD Million (2023-2028)
  • Table 229. Brazil Artificial Blood, by End-use USD Million (2023-2028)
  • Table 230. Argentina Artificial Blood, by Type USD Million (2023-2028)
  • Table 231. Argentina Artificial Blood, by Application USD Million (2023-2028)
  • Table 232. Argentina Artificial Blood, by End-use USD Million (2023-2028)
  • Table 233. Rest of South America Artificial Blood, by Type USD Million (2023-2028)
  • Table 234. Rest of South America Artificial Blood, by Application USD Million (2023-2028)
  • Table 235. Rest of South America Artificial Blood, by End-use USD Million (2023-2028)
  • Table 236. Asia Pacific Artificial Blood, by Country USD Million (2023-2028)
  • Table 237. Asia Pacific Artificial Blood, by Type USD Million (2023-2028)
  • Table 238. Asia Pacific Artificial Blood, by Application USD Million (2023-2028)
  • Table 239. Asia Pacific Artificial Blood, by End-use USD Million (2023-2028)
  • Table 240. China Artificial Blood, by Type USD Million (2023-2028)
  • Table 241. China Artificial Blood, by Application USD Million (2023-2028)
  • Table 242. China Artificial Blood, by End-use USD Million (2023-2028)
  • Table 243. Japan Artificial Blood, by Type USD Million (2023-2028)
  • Table 244. Japan Artificial Blood, by Application USD Million (2023-2028)
  • Table 245. Japan Artificial Blood, by End-use USD Million (2023-2028)
  • Table 246. India Artificial Blood, by Type USD Million (2023-2028)
  • Table 247. India Artificial Blood, by Application USD Million (2023-2028)
  • Table 248. India Artificial Blood, by End-use USD Million (2023-2028)
  • Table 249. South Korea Artificial Blood, by Type USD Million (2023-2028)
  • Table 250. South Korea Artificial Blood, by Application USD Million (2023-2028)
  • Table 251. South Korea Artificial Blood, by End-use USD Million (2023-2028)
  • Table 252. Taiwan Artificial Blood, by Type USD Million (2023-2028)
  • Table 253. Taiwan Artificial Blood, by Application USD Million (2023-2028)
  • Table 254. Taiwan Artificial Blood, by End-use USD Million (2023-2028)
  • Table 255. Australia Artificial Blood, by Type USD Million (2023-2028)
  • Table 256. Australia Artificial Blood, by Application USD Million (2023-2028)
  • Table 257. Australia Artificial Blood, by End-use USD Million (2023-2028)
  • Table 258. Rest of Asia-Pacific Artificial Blood, by Type USD Million (2023-2028)
  • Table 259. Rest of Asia-Pacific Artificial Blood, by Application USD Million (2023-2028)
  • Table 260. Rest of Asia-Pacific Artificial Blood, by End-use USD Million (2023-2028)
  • Table 261. Europe Artificial Blood, by Country USD Million (2023-2028)
  • Table 262. Europe Artificial Blood, by Type USD Million (2023-2028)
  • Table 263. Europe Artificial Blood, by Application USD Million (2023-2028)
  • Table 264. Europe Artificial Blood, by End-use USD Million (2023-2028)
  • Table 265. Germany Artificial Blood, by Type USD Million (2023-2028)
  • Table 266. Germany Artificial Blood, by Application USD Million (2023-2028)
  • Table 267. Germany Artificial Blood, by End-use USD Million (2023-2028)
  • Table 268. France Artificial Blood, by Type USD Million (2023-2028)
  • Table 269. France Artificial Blood, by Application USD Million (2023-2028)
  • Table 270. France Artificial Blood, by End-use USD Million (2023-2028)
  • Table 271. Italy Artificial Blood, by Type USD Million (2023-2028)
  • Table 272. Italy Artificial Blood, by Application USD Million (2023-2028)
  • Table 273. Italy Artificial Blood, by End-use USD Million (2023-2028)
  • Table 274. United Kingdom Artificial Blood, by Type USD Million (2023-2028)
  • Table 275. United Kingdom Artificial Blood, by Application USD Million (2023-2028)
  • Table 276. United Kingdom Artificial Blood, by End-use USD Million (2023-2028)
  • Table 277. Netherlands Artificial Blood, by Type USD Million (2023-2028)
  • Table 278. Netherlands Artificial Blood, by Application USD Million (2023-2028)
  • Table 279. Netherlands Artificial Blood, by End-use USD Million (2023-2028)
  • Table 280. Rest of Europe Artificial Blood, by Type USD Million (2023-2028)
  • Table 281. Rest of Europe Artificial Blood, by Application USD Million (2023-2028)
  • Table 282. Rest of Europe Artificial Blood, by End-use USD Million (2023-2028)
  • Table 283. MEA Artificial Blood, by Country USD Million (2023-2028)
  • Table 284. MEA Artificial Blood, by Type USD Million (2023-2028)
  • Table 285. MEA Artificial Blood, by Application USD Million (2023-2028)
  • Table 286. MEA Artificial Blood, by End-use USD Million (2023-2028)
  • Table 287. Middle East Artificial Blood, by Type USD Million (2023-2028)
  • Table 288. Middle East Artificial Blood, by Application USD Million (2023-2028)
  • Table 289. Middle East Artificial Blood, by End-use USD Million (2023-2028)
  • Table 290. Africa Artificial Blood, by Type USD Million (2023-2028)
  • Table 291. Africa Artificial Blood, by Application USD Million (2023-2028)
  • Table 292. Africa Artificial Blood, by End-use USD Million (2023-2028)
  • Table 293. North America Artificial Blood, by Country USD Million (2023-2028)
  • Table 294. North America Artificial Blood, by Type USD Million (2023-2028)
  • Table 295. North America Artificial Blood, by Application USD Million (2023-2028)
  • Table 296. North America Artificial Blood, by End-use USD Million (2023-2028)
  • Table 297. United States Artificial Blood, by Type USD Million (2023-2028)
  • Table 298. United States Artificial Blood, by Application USD Million (2023-2028)
  • Table 299. United States Artificial Blood, by End-use USD Million (2023-2028)
  • Table 300. Canada Artificial Blood, by Type USD Million (2023-2028)
  • Table 301. Canada Artificial Blood, by Application USD Million (2023-2028)
  • Table 302. Canada Artificial Blood, by End-use USD Million (2023-2028)
  • Table 303. Mexico Artificial Blood, by Type USD Million (2023-2028)
  • Table 304. Mexico Artificial Blood, by Application USD Million (2023-2028)
  • Table 305. Mexico Artificial Blood, by End-use USD Million (2023-2028)
  • Table 306. Artificial Blood Sales: by Type(K Units)
  • Table 307. Artificial Blood Sales Human Blood , by Region K Units (2023-2028)
  • Table 308. Artificial Blood Sales Synthetic Blood , by Region K Units (2023-2028)
  • Table 309. Artificial Blood Sales Animal Blood , by Region K Units (2023-2028)
  • Table 310. Artificial Blood Sales: by Application(K Units)
  • Table 311. Artificial Blood Sales Cardiovascular diseases , by Region K Units (2023-2028)
  • Table 312. Artificial Blood Sales Anemia , by Region K Units (2023-2028)
  • Table 313. Artificial Blood Sales Organ transplant , by Region K Units (2023-2028)
  • Table 314. Artificial Blood Sales Trauma , by Region K Units (2023-2028)
  • Table 315. Artificial Blood Sales Others , by Region K Units (2023-2028)
  • Table 316. Artificial Blood Sales: by End-use(K Units)
  • Table 317. Artificial Blood Sales Hospitals , by Region K Units (2023-2028)
  • Table 318. Artificial Blood Sales Clinics , by Region K Units (2023-2028)
  • Table 319. Artificial Blood Sales Blood banks , by Region K Units (2023-2028)
  • Table 320. Artificial Blood Sales Others , by Region K Units (2023-2028)
  • Table 321. South America Artificial Blood Sales, by Country K Units (2023-2028)
  • Table 322. South America Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 323. South America Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 324. South America Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 325. Brazil Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 326. Brazil Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 327. Brazil Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 328. Argentina Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 329. Argentina Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 330. Argentina Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 331. Rest of South America Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 332. Rest of South America Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 333. Rest of South America Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 334. Asia Pacific Artificial Blood Sales, by Country K Units (2023-2028)
  • Table 335. Asia Pacific Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 336. Asia Pacific Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 337. Asia Pacific Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 338. China Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 339. China Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 340. China Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 341. Japan Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 342. Japan Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 343. Japan Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 344. India Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 345. India Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 346. India Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 347. South Korea Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 348. South Korea Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 349. South Korea Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 350. Taiwan Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 351. Taiwan Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 352. Taiwan Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 353. Australia Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 354. Australia Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 355. Australia Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 356. Rest of Asia-Pacific Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 357. Rest of Asia-Pacific Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 358. Rest of Asia-Pacific Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 359. Europe Artificial Blood Sales, by Country K Units (2023-2028)
  • Table 360. Europe Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 361. Europe Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 362. Europe Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 363. Germany Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 364. Germany Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 365. Germany Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 366. France Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 367. France Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 368. France Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 369. Italy Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 370. Italy Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 371. Italy Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 372. United Kingdom Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 373. United Kingdom Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 374. United Kingdom Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 375. Netherlands Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 376. Netherlands Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 377. Netherlands Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 378. Rest of Europe Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 379. Rest of Europe Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 380. Rest of Europe Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 381. MEA Artificial Blood Sales, by Country K Units (2023-2028)
  • Table 382. MEA Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 383. MEA Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 384. MEA Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 385. Middle East Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 386. Middle East Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 387. Middle East Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 388. Africa Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 389. Africa Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 390. Africa Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 391. North America Artificial Blood Sales, by Country K Units (2023-2028)
  • Table 392. North America Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 393. North America Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 394. North America Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 395. United States Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 396. United States Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 397. United States Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 398. Canada Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 399. Canada Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 400. Canada Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 401. Mexico Artificial Blood Sales, by Type K Units (2023-2028)
  • Table 402. Mexico Artificial Blood Sales, by Application K Units (2023-2028)
  • Table 403. Mexico Artificial Blood Sales, by End-use K Units (2023-2028)
  • Table 404. Artificial Blood: by Type(USD/Units)
  • Table 405. Research Programs/Design for This Report
  • Table 406. Key Data Information from Secondary Sources
  • Table 407. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Artificial Blood: by Type USD Million (2017-2022)
  • Figure 5. Global Artificial Blood: by Application USD Million (2017-2022)
  • Figure 6. Global Artificial Blood: by End-use USD Million (2017-2022)
  • Figure 7. South America Artificial Blood Share (%), by Country
  • Figure 8. Asia Pacific Artificial Blood Share (%), by Country
  • Figure 9. Europe Artificial Blood Share (%), by Country
  • Figure 10. MEA Artificial Blood Share (%), by Country
  • Figure 11. North America Artificial Blood Share (%), by Country
  • Figure 12. Global Artificial Blood: by Type K Units (2017-2022)
  • Figure 13. Global Artificial Blood: by Application K Units (2017-2022)
  • Figure 14. Global Artificial Blood: by End-use K Units (2017-2022)
  • Figure 15. South America Artificial Blood Share (%), by Country
  • Figure 16. Asia Pacific Artificial Blood Share (%), by Country
  • Figure 17. Europe Artificial Blood Share (%), by Country
  • Figure 18. MEA Artificial Blood Share (%), by Country
  • Figure 19. North America Artificial Blood Share (%), by Country
  • Figure 20. Global Artificial Blood: by Type USD/Units (2017-2022)
  • Figure 21. Global Artificial Blood share by Players 2022 (%)
  • Figure 22. Global Artificial Blood share by Players (Top 3) 2022(%)
  • Figure 23. Global Artificial Blood share by Players (Top 5) 2022(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Dextro-Sang Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 26. Dextro-Sang Corporation (United States) Revenue: by Geography 2022
  • Figure 27. BioPure Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. BioPure Corporation (United States) Revenue: by Geography 2022
  • Figure 29. Sangart (United States) Revenue, Net Income and Gross profit
  • Figure 30. Sangart (United States) Revenue: by Geography 2022
  • Figure 31. Northfield Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 32. Northfield Laboratories (United States) Revenue: by Geography 2022
  • Figure 33. Baxter International (United States) Revenue, Net Income and Gross profit
  • Figure 34. Baxter International (United States) Revenue: by Geography 2022
  • Figure 35. FluorO2 Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 36. FluorO2 Therapeutics (United States) Revenue: by Geography 2022
  • Figure 37. Nuvox Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 38. Nuvox Pharma (United States) Revenue: by Geography 2022
  • Figure 39. Alpha Therapeutic Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 40. Alpha Therapeutic Corporation (United States) Revenue: by Geography 2022
  • Figure 41. HemoBioTech (United States) Revenue, Net Income and Gross profit
  • Figure 42. HemoBioTech (United States) Revenue: by Geography 2022
  • Figure 43. Hemarina (France) Revenue, Net Income and Gross profit
  • Figure 44. Hemarina (France) Revenue: by Geography 2022
  • Figure 45. Global Artificial Blood: by Type USD Million (2023-2028)
  • Figure 46. Global Artificial Blood: by Application USD Million (2023-2028)
  • Figure 47. Global Artificial Blood: by End-use USD Million (2023-2028)
  • Figure 48. South America Artificial Blood Share (%), by Country
  • Figure 49. Asia Pacific Artificial Blood Share (%), by Country
  • Figure 50. Europe Artificial Blood Share (%), by Country
  • Figure 51. MEA Artificial Blood Share (%), by Country
  • Figure 52. North America Artificial Blood Share (%), by Country
  • Figure 53. Global Artificial Blood: by Type K Units (2023-2028)
  • Figure 54. Global Artificial Blood: by Application K Units (2023-2028)
  • Figure 55. Global Artificial Blood: by End-use K Units (2023-2028)
  • Figure 56. South America Artificial Blood Share (%), by Country
  • Figure 57. Asia Pacific Artificial Blood Share (%), by Country
  • Figure 58. Europe Artificial Blood Share (%), by Country
  • Figure 59. MEA Artificial Blood Share (%), by Country
  • Figure 60. North America Artificial Blood Share (%), by Country
  • Figure 61. Global Artificial Blood: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Dextro-Sang Corporation (United States)
  • BioPure Corporation (United States)
  • Sangart (United States)
  • Northfield Laboratories (United States)
  • Baxter International (United States)
  • FluorO2 Therapeutics (United States)
  • Nuvox Pharma (United States)
  • Alpha Therapeutic Corporation (United States)
  • HemoBioTech (United States)
  • Hemarina (France)
Select User Access Type

Key Highlights of Report


May 2023 214 Pages 63 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Artificial Blood Quantitative research analysis
Global Artificial Blood Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2022; Base year: 2022; Forecast period: 2023 to 2028
Companies that are profiled in Global Artificial Blood Market are Dextro-Sang Corporation (United States), BioPure Corporation (United States), Sangart (United States), Northfield Laboratories (United States), Baxter International (United States), FluorO2 Therapeutics (United States), Nuvox Pharma (United States), Alpha Therapeutic Corporation (United States), HemoBioTech (United States) and Hemarina (France) etc.
Cardiovascular diseases segment in Global market to hold robust market share owing to "Rising demand for blood transfusion ".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Artificial Blood market throughout the forecasted period.

Know More About Global Artificial Blood Report?

Have a Query? Click Here

Other Related Reports

Cryogenic Biobanking Services Comprehensive Study by Type (Ice Machines, Freezers, Alarms And Monitoring System, Refrigerators, Cryogenic Storage Systems, Accessories), Application (Biobaking, Regene...
$ 3750
Gastritis Treatment Comprehensive Study by Type (Acid Blocking Medications, Acid Reducing Medications, Antacids, Antibiotics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, On...
$ 3650
Medical Wellness Comprehensive Study by Type (Complementary and Alternative Medicine, Beauty Care and Anti-Aging, Preventative & Personalized Medicine and Public Health, Healthy Eating, Nutrition & W...
$ 3450
Vision Care Comprehensive Study by Type (Eye Glasses {Single Vision Eyeglasses, Bifocal Eyeglasses, Progressive Eyeglasses}, Contact Lens {Personalized/Custom, Specific Care, Single Vision, Progressi...
$ 3750
Collagen Meniscus Implant Comprehensive Study by Application (Adult, Pediatric), End-Use (Hospital, Clinic, Medical Center, Others) Players and Region - Global Market Outlook to 2030
$ 3500
Flies Repellent Comprehensive Study by Type (Sprays/Aerosol, Liquid Vaporizers, Coils, Cream & Oil, Electronic Devices, Others (Chalk, Powder)), Distribution Channel (Online, Offline (Organized Retai...
$ 3650